Inipharm, Inc is a biopharmaceutical company based in Bellevue, WA, dedicated to the discovery and development of therapies for severe liver diseases. Their lead program focuses on targeting the genetically-defined target, HSD17B13, which has been consistently associated with lower rates and severity of multiple liver diseases. Inipharm is advancing a pipeline of small-molecule therapies that target the activity of this protein, with a particular focus on treating fibrotic liver diseases.
With a team of experienced leaders in the healthcare industry, including their Co-Founder and CEO, Brian Farmer, and Co-Founder and Chief Scientific Officer, Heather Hsu, Inipharm is committed to developing highly validated approaches to address the unmet needs in severe liver diseases. Their research and development efforts have shown promising results in human liver cell-based systems, demonstrating anti-fibrotic effects and improved liver enzymes in multiple in vivo models.
Generated from the website